Many of our clients are looking for ways to ensure their Patient Support Program (PSP) is not only serving their patient and provider populations well but that it is doing so in a fiscally responsible way.…
Pharmaceutical manufacturers rely on national account managers (NAMs) to build relationships, negotiate contracts and get their products in front of payers and pharmacy benefit managers who will clear the way for patient treatment coverage. Challenges Facing…
FRMs, sometimes referred to as field reimbursement specialists or patient experience specialists, are the key drivers in patient pre-authorization and billing and coding processes, and play a vital role in the prescription and adoption of specialty…
“It is not how much you have or know, or even who you know; it is how well you adapt to the inevitable changes along the way. As Heraclitus, the Greek philosopher, said, ‘Change is the…
Posted by
Dr. Richard Stefanacci on 5月 21, 20215/21/21
In a market where all healthcare stakeholders expect more from manufacturers, payers are no exception. As payers work to support patients and meet their own industry needs, manufacturers need to understand payer processes to improve patient…
The Centers for Medicare and Medicaid Services (CMS) again delayed implementation of the Medicare Coverage of Innovative Technology (MCIT) program, now until December 15, 2021. The program, as described in the current and preceding rules, will…
The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization and underutilization. Moving forward, the more diligent payers…
Global healthcare and life sciences innovation continues to surge at an unprecedented rate, and government entities worldwide are trying to keep up. Price transparency and treatment affordability remain at the top of the list for legislative concern. For instance, United States…
Pricing system pressures are increasing for the top four markets in Europe. Price transparency, changes to public health plans and curative therapies are set to disrupt traditional drug pricing. To navigate this ever-shifting landscape, companies must…
As the world strives every day to adapt to changes this year, one change that pharma manufacturers are adapting to is the impact of COVID-19 on product safety audits. From supplier audits to evaluating internal or affiliated sites with…